Table 1

Clinical and virological characteristics of the 20 HALT-C patients.

Patient

Age

Gender

Genotype

Serum HCV RNA at W00 (log10)

Diversity

Complexity


Taq

HF-2

Taq

HF-2


1

52

M

1a

6.55

0.9953

1.0000

7

1

2

54

F

1b

6.49

0.9905

1.0000

5

1

3

51

M

1a/b

6.99

0.9958

1.0000

5

1

4

42

M

1a

6.81

0.9877

0.9894

6

2

5

56

M

1a

7.13

0.9979

1.0000

4

1

6

42

M

1

6.55

0.9903

0.9912

8

6

7

73

M

1b

6.78

0.9892

0.9877

7

5

8

45

M

1

6.37

0.9193

0.9805

7

6

9

53

M

1a

7.06

0.9954

1.0000

2

1

10

47

M

1b

6.35

0.9845

0.9994

4

3

11

19

M

1b

5.72

0.9964

0.9994

2

2

12

49

M

1a

7.06

0.9979

0.9986

3

3

13

42

F

1b

6.26

0.9993

0.9781

2

2

14

42

M

1a

7.30

0.9810

0.9685

8

9

15

61

M

1b

5.85

0.9858

0.9624

4

5

16

54

M

1b

6.93

0.9047

0.9409

6

9

17

45

F

1a

6.72

0.9962

0.9917

2

5

18

47

F

1a

6.14

0.9966

0.9984

4

2

19

50

M

1a

6.37

0.9962

0.9968

4

3

20

53

M

1a

5.81

0.989

0.9943

6

5

AVG

48.85

6.56

0.9845

0.9889

4.8

3.6


HCV genotypes were determined by INNO-LiPA. HCV RNA was quantified with the Roche COBAS Monitor assay, and is expressed as log10 IU/mL. QS heterogeneity was assessed using the clonal frequency analysis (CFA) technique. Diversity scores represent the average heteroduplex mobility ratios (HMR) for either Taq or HF-2 enzymes. Complexity scores represent the total number of distinct gel shift variants analyzed by CFA. W00 represents the week 0 or baseline sample. AVG represents average.

Polyak et al. Virology Journal 2005 2:41   doi:10.1186/1743-422X-2-41

Open Data